The chronic effects of thiamin on cardiovascular risk factors in individuals with hyperglycaemia

thiamin supplementation in those with hyperglycaemia: impact on blood lipids, microalbuminaemia and endothelial dysfunction

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000051943

Enrollment

Registered

2011-01-14

Start date

2009-05-12

Completion date

2010-05-23

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Thiamin or benfotiamine supplementation has been shown to have positive effects on CVD risk factors in animals with experimental diabetes and a few studies of humans with diabetes. This study is designed to see if thiamin has benefts in those with glucose intolerance.

Interventions

100 mg thiamin taken as an oral capsule 3 times per day for 6 weeks in a crossover design which includes a wash-out of approximately 3 mo. After the 3 month wash-out, participants will move onto the placebo treatment and vice versa in the control group.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

hyperglycaemic volunteers with body mass index (BMI) 19-40

Exclusion criteria

smoking, known impaired renal or liver function, cardiovascular disease (CVD) event over the last 6 mo, more than 2 std drinks per day, systemic illnesses or use of medications, known allergy or intolerance to thiamin; use of all supplements containing thiamin; pregnancy or lactation

Outcome results